New preclinical data on the antifibrotic effects of tasquinimod in myelofibrosis to be presented at EHA 2023
New data on the mechanisms by which tasquinimod ameliorates bone marrow fibrosis in a murine model of myelofibrosis will be presented in an oral session at the European Hematology Association Congress in Frankfurt, 8-11 June, 2023.
Previous studies have shown the importance of the alarmin complex S100A8/S100A9 in the pathogenesis of myelofibrosis (MF). Tasquinimod is a small molecule oral inhibitor of S100A9 and it has shown disease inhibitory effects in preclinical models of MF. The data to be presented further elucidates the mechanisms by which tasquinimod reduces fibrosis in experimental MF.
Tasquinimod was shown to reduce the pathogenic alarmin signalling, originating from the hematopoietic cells, and cross-talk with stromal cells. The data indicate a direct effect on fibrosis with tasquinimod due to reduced interactions between megakaryocytes and stromal cells. Additionally, tasquinimod induced apoptosis in the malignant hematopoietic cells.
In the next step a clinical trial, TasqForce MPN, with tasquinimod in patients with MF will start during 2023.
Details on the presentation:
- Abstract Title: Inhibiting the alarmin-driven hematopoiesis-stromal cells crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis
- Session Title: Scientific updates in MPN
- Abstract ID: 3870
- Session Date and Time: Saturday June 10, 4:30 PM
The abstract is available on the EHA website https://library.ehaweb.org/eha